RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Looks like a very reasonable, pragmatic approach. The question is: Can Cortex now raise the money necessary for the next set of clinical studies? The good news is that the climate for CNS funding is hugely different than it was even a year ago at this time. To illustrate:

The level of VC/institutional/secondary offering proceeds raised by small CNS companies was devastated from 2007-13.

2006: (millions) 1922
2007: 978.7
2008: 839
2009: 826
2010: 917
2011: 604
2012: 954
2013: 957

2014, YTD: 2669.

YTD the total financing raised is almost triple what it was last year. There is a dramatic increase in funding, and most of it is not due to the ten IPOs in the CNS sector thus far in 2014, but those IPOs give VCs the reassurance that there will be an exit available. CNS has regained credibility, which gives Lippa a much better chance of attracting the funding he needs.

NeuroPerspective